U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H18FN3O3
Molecular Weight 319.3308
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of NORFLOXACIN

SMILES

CCN1C=C(C(O)=O)C(=O)C2=C1C=C(N3CCNCC3)C(F)=C2

InChI

InChIKey=OGJPXUAPXNRGGI-UHFFFAOYSA-N
InChI=1S/C16H18FN3O3/c1-2-19-9-11(16(22)23)15(21)10-7-12(17)14(8-13(10)19)20-5-3-18-4-6-20/h7-9,18H,2-6H2,1H3,(H,22,23)

HIDE SMILES / InChI
Molecular Formula C16H18FN3O3
Molecular Weight 319.3308
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Norfloxacin is an antibacterial agent, It inhibits inhibits DNA synthesis by inhibiting DNA gyrase enzyme. Norfloxacin was approved in 1986 for treatment of urinary tract infections, gynecological infections, prostatitis, gonorhhea and bladder infections. In ophtalmology, norfloxacin is used for treatment of conjunctivitus.

CNS Activity

Originator

Approval Year

1986
149
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
6502
Urinary Tract Infections
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
DNA topoisomerase II beta
Approved
7817
NOROXIN
Primary
DNA topoisomerase II beta
Approved
7817
CHIBROXIN
Primary
DNA topoisomerase II beta
Approved
7817
NOROXIN
Primary
DNA topoisomerase II beta
Approved
7817
NOROXIN
PubMed

PubMed

TitleDatePubMed
Structure-activity relationships of antibacterial 6,7- and 7,8-disubstituted 1-alkyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acids.
1980 Dec
Norfloxacin versus co-trimoxazole in the treatment of recurring urinary tract infections in men.
1986
World-wide clinical experience with norfloxacin: efficacy and safety.
1986
Norfloxacin in the treatment of uncomplicated gonococcal infections.
1987 Jun 26
In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
2001
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.
2001 Nov
Treatment of malignant biliary stenosis: which stent to use?
2001 Oct-Dec
Comparison of aztreonam against other antibiotics used in urinary tract infections.
2001 Oct-Dec
Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats.
2002 Feb
[Acute pancreatitis secondary to administration or norfloxacin].
2002 Jan
Resistance of Klebsiella pneumoniae strains producing and not producing ESBL (extended-spectrum beta-lactamase) type enzymes to selected non-beta-lactam antibiotics.
2002 Mar
Rapid antimicrobial susceptibility testing of urinary tract isolates and samples by flow cytometry.
2002 Mar
Patents

Patents

4472579
18
5051505
8
5162523
4
6492373
4
JP2007537168A
7
JP2009018993A
7
JP2009501065A
29
JP2011528275A
404
JP4849764B2
70
JPH08193024A
4
JPS62294689A
4
JPS63190826A
4
US4146719
4

Sample Use Guides

In Vivo Use Guide
Norfloxacin tablets is administered orally with a glass of water at least 1 hour before or at least 2 hours after a meal or dairy products (e.g., milk, yogurt). Patients receiving norfloxacin should be well hydrated and should be instructed to drink fluids liberally. The maximal oral dose is 400 mg. For treatment of conjunctivitus, norfloxacin should be instilled at 1 or 2 drops to the affected eye(s) 4 times daily for up to 7 days.
Route of Administration: oral; topical
In Vitro Use Guide
Minimal inhibition concnetration of norfloxacin aganis S.aureus, E.coli and P.aeuginosa was determined using agar media by means of a standard twofold serial dilution method and comprised 0.39, 0.05 and 0.39 ug/mL correspondingly.
Substance Class Chemical
Created
by admin
on Tue Mar 06 11:23:17 UTC 2018
Edited
by admin
on Tue Mar 06 11:23:17 UTC 2018
Record UNII
N0F8P22L1P
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
NORFLOXACIN
EP   INN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
NORFLOXACIN [MI]
Common Name English
NORFLOXACIN [VANDF]
Common Name English
NORFLOXACIN [USP]
Common Name English
NORFLOXACIN [WHO-DD]
Common Name English
NORFLOXACIN [USP-RS]
Common Name English
NORFLOXACIN [EP]
Common Name English
MK-366
Code English
NOROXIN
Brand Name English
NORFLOXACIN [USAN]
Common Name English
NORFLOXACIN [INN]
Common Name English
NORFLOXACIN [MART.]
Common Name English
CHIBROXIN
Brand Name English
3-QUINOLINECARBOXYLIC ACID, 1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-
Common Name English
NORFLOXACIN [ORANGE BOOK]
Common Name English
1-ETHYL-6-FLUORO-1,4-DIHYDRO-4-OXO-7-(1-PIPERAZINYL)-3-QUINOLINE CARBOXYLIC ACID
Systematic Name English
Classification Tree Code System Code
WHO-VATC QS01AE02
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
LIVERTOX 697
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
NDF-RT N0000007606
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
WHO-VATC QJ01MA06
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
WHO-ATC S01AE02
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
WHO-ATC J01RA13
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
WHO-ATC J01MA06
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
NDF-RT N0000175937
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
WHO-ATC S01AX12
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
Code System Code Type Description
NCI_THESAURUS
C47638
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
DRUG BANK
DB01059
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
ChEMBL
CHEMBL9
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
MESH
D009643
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
RXCUI
7517
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY RxNorm
EVMPD
SUB09365MIG
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
ECHA (EC/EINECS)
274-614-4
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
WIKIPEDIA
NORFLOXACIN
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
LactMed
70458-96-7
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
MERCK INDEX
M8059
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY Merck Index
INN
5105
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
HSDB
70458-96-7
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
EPA CompTox
70458-96-7
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
CAS
70458-96-7
Created by admin on Tue Mar 06 11:23:17 UTC 2018 , Edited by admin on Tue Mar 06 11:23:17 UTC 2018
PRIMARY
Related Record Type Details
Structure of NORFLOXACIN
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966